April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Pegaptanib Sodium for Clinically Significant Diabetic Macular Edema in Poor Candidates for Standard Transpupil Focal/Grid Photocoagulation: Results of a Retrospective Case Series
Author Affiliations & Notes
  • C. J. Beck
    Central Plains Eye MDs, Wichita, Kansas
  • K. A. Darden
    Central Plains Eye MDs, Wichita, Kansas
  • Footnotes
    Commercial Relationships  C.J. Beck, None; K.A. Darden, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4228. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. J. Beck, K. A. Darden; Pegaptanib Sodium for Clinically Significant Diabetic Macular Edema in Poor Candidates for Standard Transpupil Focal/Grid Photocoagulation: Results of a Retrospective Case Series. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4228.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess anatomic and functional outcomes after intravitreal selective vascular endothelial growth factor (VEGF) inhibition in eyes with clinically significant diabetic macular edema (DME) harboring foveal avascular zone enlargement and/or central microaneurysms ineligible for standard laser per Early Treatment Diabetic Retinopathy Study (ETDRS).

Methods: : Retrospective chart review of patients diagnosed with clinically significant DME not treated by standard transpupil focal/grid photocoagulation within preceeding one year. Selected cases featured angiographically enlarged foveal avascular zone and/or patent microaneurysms located at the foveal avascular margin. Assesments included visual acuity (VA), central subfield thickness (CST) analysis by spectral domain optical coherence tomography, and fluorescein angiography. All clinical examinations were conducted by a single retinologist (CJB) and all intravitreal injections were performed by a single, separate provider (KAD).

Results: : To date, 10 eyes of 10 patients ages 40-82 years with DME received a mean of 1.7±0.7 intravitreal injections of pegaptanib over a course of 4.5+1.6 months (range: 2-7). Mean VA decreased from 0.3±0.3 to 0.1±0.2 LogMAR. The baseline VA was maintained in 80% of treated eyes with 40% gaining ≥3 lines VA and 90% losing <3 lines. No eyes required adjunctive rescue therapy via standard transpupil focal/grid photocoagulation and/or nonselective VEGF inhibitor Rx and/or intraocular corticosteroid Rx. Mean CST increased from 259±46 microns to 275±55 microns. This delta was not statistically significant (paired t-test: p=0.22).

Conclusions: : Short-term outcomes suggest intravitreal pegaptanib not only maintains but improves VA in eyes with clinically significant DME which are not ideal candidates for standard laser therapy. An apparent disconnect between functional and anatomical trends does not negate the positive results shown. Longer follow-up data will be presented.

Keywords: diabetes • retina • edema 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×